Date: 2012-10-15
Type of information: Services contract
Compound: discovery services in the areas of chemistry, drug metabolism and pharmacokinetics (DMPK), and efficacy screening
Company: Pharmaron (China) AstraZeneca (UK)
Therapeutic area:
Type agreement: services
Action mechanism:
Disease:
Details: Pharmaron, a premier R&D service provider for the pharmaceutical and biotech industries, has announced a drug discovery partnership with AstraZeneca to support their global Innovative Medicines Units.
Under this multi-year agreement, Pharmaron will provide AstraZeneca with discovery services in the areas of chemistry, drug metabolism and pharmacokinetics (DMPK), and efficacy screening.
Pharmaron will conduct these services with a team consisting of several hundred scientists in dedicated, state-of-the-art research laboratories located in its newly opened drug discovery service center in Beijing. The co-location of screening and chemistry services at a single partner is expected to help AstraZeneca scientists drive their drug discovery programs with greater efficiency.
Financial terms: Financial details of the deal were not disclosed.
Latest news:
